{
    "title": "LifeMD Stock Inflates as GLP-1 Trend Drives Revenue and Earnings",
    "date": "3/19/2024",
    "url": "https://www.marketbeat.com/stock-ideas/lifemd-shares-come-back-to-life-on-glp-1-business-growth/",
    "text": " LifeMD Inc. NASDAQ: LFMD provides telehealth services to consumers in the United States. The medical sector company operates many telehealth brands, including men's telehealth brands RexMD and ShapiroMD, NavaMD female dermatology telehealth, Cleared Allergy Clinic, and LifeMD Primary Care. The company provides primary care, chronic care management, dermatology, and various specialties using a direct-to-consumer (DTC) model. It offers a convenient, accessible channel for consumers who seek medical treatments and consults quickly and virtually. The company commenced its GLP-1 clinical weight management program in 2023, shortly after WW International Inc. NASDAQ: WW entered the clinical weight loss segment with its acquisition of Sequence Inc., which offers membership plans enabling GLP-1 prescriptions from its providers. LifeMD teamed up with weight management company Medifast Inc. NYSE: MED, which committed a $20 million investment to collaborate with its Optavia coaching program. Its GLP-1 business has grown to over 22,000 patient subscribers and 100% quarter-over-quarter (QoQ). LifeMD competes with peer telehealth platforms, including Hims & Hers Inc. NYSE: HIMS, American Well Co. NYSE: AMWL and \u00a0Teladoc Inc. NYSE: TDOC, LifeMD offers no insurance needed plan options, and a partnership with Laboratory Co. of America Holdings NYSE: LH and Quest Diagnostics Inc. NYSE: DGX provides access to discounted lab services. Its FlexCare plan requires no membership, as patients can schedule virtual doctor visits for a flat $139 per visit and a free membership to LifeMD's prescription discount card. Its TotalCare plan provides a free virtual visit every month, including free appointments and all benefits from the FlexCare plan for a $117 quarterly membership. It\u2019s ConciergeCare plan has unlimited free visits, and all benefit from the TotalCare plan for $99 a month. LifeMD's GLP-1 Program costs $129 per month. It includes access to GLP-1 medications, including Novo Nordisk A/S NYSE: NVO Ozempic and Wegovy or Eli Lilly and Co. NYSE: LLY Mounjaro and Zepbound along with physician care, metabolic testing, insurance assistance and clinical guidance. The cost for the medications is not included, just the prescriptions and medical advice. Get AI-powered insights on MarketBeat. \u00a0Check out the sector heatmap on MarketBeat. LifeMD reported Q4 2023 EPS of 15 cents, beating consensus analyst estimates for a loss of 14 cents by 29 cents. Consolidated adjusted EBITDA was $5.5 million versus $1 million in the year-ago period. Weight management subscribers rose to 22,000 by the end of the year. GAAP net loss was $4.5 million versus $12.7 million in the year-ago period. Telehealth subscribers rose 27% YoY to a record 215,000. Revenues surged 60% YoY to $44.96 million, beating $40.48 million consensus analyst estimates. Gross margin expanded to a record 88.1%, up from 85.5% in the year-ago period. Telehealth revenues surged 90% YoY and 28% sequentially. Active telehealth subscribers rose 27% YoY to 215,000. LifeMD raised its Q1 2024 revenue guidance to $42 million to $43 million versus $42.5 million consensus estimates. It raised full-year 2024 revenues of at least $200 million versus $191.5 million consensus estimates. That was up from its $195 million to $205 million prior guidance. LifeMD CEO Justin Schreiber commented, \"During the year, we launched our GLP-1 weight management program, which has rapidly grown to become one of the leading providers of medically supported weight loss management services nationwide. In less than nine months, we scaled this business to over 22,000 subscribers and growing. Year to date, in 2024, we continue to see record daily performance in the sale of new weight management subscriptions at a rate in excess of our previous 2024 guidance.\" LifeMD analyst ratings and price targets are at MarketBeat. LifeMD peers and competitor stocks can be found with the MarketBeat stock screener.  The daily candlestick chart for LFMD illustrates a daily cup and handle breakout pattern. The cup lip lines formed at $8.44 on January 3, 2024. Shares fell to a low of $5.00 on January 4, 2024. LFMD formed a rounding bottom over the next several months to stage a rally back to retest the lip line at $8.44 on February 27, 2024. LFMD pulled back to form a handle heading to its Q4 2023 earnings. Earnings proved to be very strong, along with raised guidance helping lift shares through the cup lip line resistance, triggering the cup and handle breakout. The daily relative strength index (RSI) surged to the overbought 80-band. Pullback support levels are at $9.11, $8.44, $7.68 and $6.97. Before you consider LifeMD, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list. While LifeMD currently has a \"Buy\" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio. Trading Strategies Jea Yu has been a contributing writer for MarketBeat since 2018. Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development Bachelor of Arts, University of Maryland, College Park U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor. MarketBeat gives you seven stocks that you should be looking at to create your own Magnificent Seven in 2024. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. As Featured By: 345 N Reid Place, Suite 620, Sioux Falls, SD 57103\n\ncontact@marketbeat.com\n\n(844) 978-6257 \u00a9 MarketBeat Media, LLC\u00ae 2010-2024. All rights reserved. \u00a9 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer. My Account - "
}